MYCN amplification remains prognostically strong 20 years after its “clinical debut”
- 1 December 2004
- journal article
- editorial
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (18) , 2639-2642
- https://doi.org/10.1016/j.ejca.2004.07.025
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid LeukemiaNew England Journal of Medicine, 2004
- MYCN-mediated regulation of the MRP1 promoter in human neuroblastomaOncogene, 2004
- Quality Assessment of Genetic Markers Used for Therapy StratificationJournal of Clinical Oncology, 2003
- Neuroblastoma: biological insights into a clinical enigmaNature Reviews Cancer, 2003
- MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplificationThe Journal of Pathology, 2002
- Myc target genesTrends in Biochemical Sciences, 1997
- Max: A Helix-Loop-Helix Zipper Protein That Forms a Sequence-Specific DNA-Binding Complex with MycScience, 1991
- Sequence-Specific DNA Binding by the c-Myc ProteinScience, 1990
- Chromosome localization in normal human cells and neuroblastomas of a gene related to c-mycNature, 1984
- Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumourNature, 1983